Management and outcomes of heart failure patients with CKD: experience from an inter‐disciplinary clinic by Nguyen, M et al.
Management and outcomes of heart failure patients
with CKD: experience from an inter-disciplinary clinic
Mai Nguyen1,2, Samir Rumjaun1, Racquel Lowe-Jones1,2, Irina Chis Ster3, Giuseppe Rosano2, Lisa Anderson2
and Debasish Banerjee1,2*
1Renal and Transplantation Unit, St George’s University Hospital NHS Foundation Trust, London, UK; 2Cardiology Clinical Academic Group, Molecular and Clinical Sciences
Research Institute, St George’s, University of London, St George’s Hospital, Grosvenor Wing Room 2.113, Blackshaw Road, Tooting, London, SW170QT, UK; and 3Institute of
Infection and Immunity, St George’s, University of London, London, UK
Abstract
Aims CKD-HF patients suffer excess hospitalization and mortality, often under-treated with life-prolonging medications due
to fear of worsening renal function and hyperkalaemia. Yet, role of inter-disciplinary working in improving therapy is unknown,
which this study aims to investigate.
Methods and results Clinical, biochemical data, and medications at first and last clinic visit were obtained from patient re-
cords for 124 patients seen in kidney failure–heart failure clinic (23 March 2017 to 11 April 2019). Medication dose groups
(none, low, and high dose), number of RAASi agents, and blood test results were compared between first and last visit in pa-
tients with at least two clinic visits (n = 97). Patient characteristics were age 78.5 years (IQR 68.1–84.4 years), male 67.7%,
diabetes 51.6%, moderate (45.2%) vs. severe (39.5%) CKD, HF with reduced ejection fraction (HFrEF) (49.2%), follow-up
234 days (IQR 121–441 days). HFrEF was associated with increased risk of death (adjusted OR 4.49, 95% CI 1.43–14.05;
P = 0.01).
Distributions of patients according to number of RAASi agents they were on differed between first and last visit (P = 0.03).
Dosage was increased in 25.9% for beta-blockers, 33.0% for ACEi/ARBs, and 17.5% for MRAs. Distributions of patients across
MRA dosage groups was different (P = 0.03), with higher proportions on higher dosages at last visit, without significant
changes in serum potassium or creatinine. Serum ferritin improved (131.0 vs. 267.5 μg/L; P < 0.001), and fewer patients
had iron deficiency (56.7% vs. 26.8%; P = 0.002) at last visit compared to the first.
Conclusions This inter-disciplinary clinic improved guideline-recommended medication prescription, MRA dosages in CKD-HF
patients without significant biochemical abnormality, and iron status. A prospectively designed study with medication titration
protocol and defined patient-centred outcomes is needed to further assess effectiveness of such clinic.
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Background
A population of patients with concurrent chronic kidney
disease (CKD) and heart failure (HF) has been increasing
due to each disease’s increasing prevalence in the aging
population as well as complex interactions between these
two disease entities. Despite their well-known survival ben-
efits in HF patients, there is no clear guidance on the use
of beta-blockers, angiotensin-converting enzyme inhibitors
(ACEis), angiotensin-receptor blockers (ARBs) and
mineralo-corticoid receptor antagonists (MRAs) in CKD–HF
patients due to exclusion of severe CKD patients from ma-
jor clinical trials.1 Clinicians often hesitate to initiate or
up-titrate renin-angiotensin-aldosterone system inhibitors
(RAASi) due to concerns regarding potential deterioration
in renal function or hyperkalaemia. CKD–HF patients, who
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already suffer high hospitalization and mortality,1 are often
under-treated with these life-prolonging medications due to
these challenges.2
A multi-disciplinary approach has been recommended for
management of CKD–HF patients due to demonstrated im-
proved patient outcomes.3–6 To our knowledge, there has
never been an inter-disciplinary clinic with input from ne-
phrologist and cardiologist for joint decision regarding medi-
cation optimization. This report describes experience of such
novel combined kidney failure–heart failure (KFHF) clinic, eval-
uating its effectiveness and exploring patient outcomes.
Methods
Criteria for referral to kidney failure–heart failure (KFHF) clinic
were concomitant CKD (stage 3 or above) and heart failure.
Patients were followed up at varying frequencies as per clin-
ical needs and discharged when they are stable on maximally
tolerated therapy of life-prolonging medications.
Patient demographics, clinical, and biochemical data
were acquired from electronic records and clinic letters.
Blood test results and doses of medications (beta-blockers,
ACEi/ARBs, and MRAs) were recorded for first and last
clinic visits. Patients were categorized into three HF sub-
groups according to ejection fraction (EF): reduced (HFrEF)
(EF < 40), mid-range (HFmEF) (40 ≤ EF < 50) and preserved
(HFpEF) (EF ≥ 50), and two CKD subgroups: moderate
(stage 3) and severe (stage 4/5/dialysis).
Effect of different variables on death was analysed using
univariate and multiple variable logistic regression analysis
and presented by the resulting odds ratios (OR) and 95% con-
fidence interval (95% CI).
Daily doses of individual therapeutic agents were catego-
rized into none, low, and high dose (≥50% of maximum dose).
Patients were categorized into none, single, and dual therapy
depending on the number of RAASi agents they were on.
These categorizations generated ordinal variables and were
analysed accordingly.
Results
KFHF clinic received 154 referrals from March 2017 to April
2019: 30 patients were excluded for non-attendance or inap-
propriate referral; 124 patients were seen and followed up,
of whom, 97 had had at least two clinic visits (hence, included
in the analysis of medication titration and blood test results).
Patient characteristics were median age 78.5 years (IQR
68.1–84.4 years), male 67.7%, diabetes mellitus 51.6%, me-
dian follow-up time 234 days (IQR 121–441 days, minimum
6 days, maximum 749 days). There was no difference among Ta
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CKD or HF subgroups with regard to patient characteristics
and baseline blood tests (Table 1).
Inpatient admission and death
Patients with HFrEF were significantly more likely to have in-
patient admissions compared to those with non-reduced EF
(60.7% vs. 40.3%; P = 0.03). They were also 4.5 times (95%
CI 1.43–14.05; P = 0.01) more likely to die; this was adjusted
for age, sex, diabetes, and CKD status (Table 2).
There was no difference in the likelihood of having hos-
pital admissions (42.6% vs. 58.9%; P = 0.10) or risk of death
(17.9% vs. 14.7%; P = 0.81) between two CKD subgroups
(Table 1).
Medications
There was some evidence which supported a difference be-
tween the first and last visit with regard to number of RAASi
agents used (P = 0.03). Proportions of patients on no RAASi
decreased from 41.2% to 29.9% while those on single or dual
therapy increased from 45.4% to 50.5% and 13.4% to 19.6%,
respectively (Figure 1). At the end of follow-up, 7.2% of pa-
tients were receiving no key therapies (beta-blockers or
RAASi agents).
Dosage was increased in 25.9% of patients for beta-
blockers, 33.0% for ACEi/ARBs, and 17.5% for MRAs. There
was no evidence to suggest any difference in distributions of
patients across dosage groups for beta-blockers (P = 0.46)
and ACEi/ARBs (P = 0.20) (Figure 2). The distribution of pa-
tients across MRA dose categories was different (P = 0.03),
with more patients being on low and high dose at the last visit
compared to the first (Figure 2). There was no significant dif-
ference in the likelihood of each medication dose being up-
titrated, across CKD and HF subgroups (Table 3).
Electrolytes and renal function
There was no overall difference in serum potassium and cre-
atinine level in patients whose ACEi/ARB and MRA dose was
increased (Table 4). Hyperkalaemia (≥5.5 mmol/L) was pres-
ent in 6.2% of patients at baseline and 10.3% at the last visit
(P = 0.29). Risk of hyperkalaemia was 6.1% among patients
with ACEi/ARB dose up-titrated, 6.3% in those with MRA dose
up-titrated.
Haemoglobin and iron management
In patients who were anaemic at the first clinic visit, mean se-
rum haemoglobin level increased (85.9 to 100.8 g/L;
P = 0.02). EPO was given to two patients.
Overall serum ferritin level increased between the first
and last clinic (131.0 vs. 267.5 μg/L; P ≤ 0.001) and propor-
tion of patients with iron deficiency decreased from 56.7%
to 26.8% (P = 0.002). Of those with iron deficiency at base-
line, 43.6% received IV iron at the same clinic visit, with a sig-
nificant increase in ferritin level (67.0 to 185.0 μg/L;
P < 0.001).
Figure 1 Comparison of proportions of patients according to number of
renin-angiotensin-aldosterone-system inhibitors (RAASi) agents used be-
tween the first and last visit (P = 0.03)
Table 2 Logistic regression analysis on effects of different variables on mortality
Univariate analyses Multiple variables analysis
Variable OR P value 95% CI for OR OR P value 95% CI for OR
Age (1 year) 1.04 0.11 0.99 1.09 1.05 0.07 1.00 1.10
Female 1.50 0.42 0.56 4.02 1.84 0.26 0.64 5.31
Diabetes 0.70 0.47 0.27 1.83 0.98 0.97 0.35 2.73
Severe CKD 1.26 0.64 0.48 3.29 1.19 0.74 0.43 3.27
HFrEF 3.72 0.02 1.26 10.99 4.49 0.01 1.43 14.05
Constanta 0.06 <0.001 0.17 0.23
aConstant: odds of death for a male patient of median age (78.5 years), non-diabetic, with moderate CKD and HF with ejection fraction
>40.
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Discussion
This study reports outcomes from the first 2 years of a
novel combined kidney failure and heart failure clinic and
its attempt to improve prescription and up-titrate dosage
of life-prolonging medications in a real-world cohort of pa-
tients with concomitant moderate or severe CKD and HF.
More patients were on single or dual RAASi therapy at
their last visit comparing to the first; the difference in
Table 3 Comparison of proportions of patients with successful medication dose up-titration among CKD and HF subgroups
Moderate CKD (%) Severe CKD (%) P value HFrEF (%) HFmEF(%) HFpEF (%) P value
Beta-blockers 34.1 16.2 0.07 25.6 29.4 24.0 0.92
ACEi/ARBs 35.3 35.9 0.95 32.6 52.4 26.1 0.16
MRAs 18.2 16.7 0.85 19.1 23.8 10.3 0.43
Table 4 Comparison of renal function, serum sodium, potassium between the first and last clinic visit in all patients with at least two
clinic visits (n = 97) or subgroups when specified
First visit Last visit P value
Na (mmol/L) 140.5 (3.5) 139.6 (4.1) 0.01
K (mmol/L) 4.6 (0.5) 4.7 (0.6) 0.43
K (ACEi/ARBs increased) 4.6 (0.5) 4.7 (0.6) 0.71
K (MRAs increased) 4.5 (0.5) 4.7 (0.6) 0.25
Creatinine (μmol/L) 188.8 (64.4) 201.5 (81.1) 0.03
Creatinine (ACEi/ARBs increased) 185.1 (59.6) 192.0 (68.9) 0.17
Creatinine (MRAs increased) 163.5 (47.8) 175.5 (36.5) 0.97
eGFR (mL/min/1.73m2) 31.5 (10.1) 29.8 (11.2) 0.02
eGFR (ACEi/ARBs increased) 32.5 (10.5) 31.6 (11.3) 0.23
eGFR (MRAs increased) 36.3 (9.4) 32.1 (6.9) 0.02
CKD stages
Stage 3 56.7% (55) 48.5% (47)
Stage 4 38.1% (37) 37.1% (36)
Stage 5 2.1% (2) 8.2% (8)
Dialysis 3.1% (3) 6.2% (6)
Hb (g/L) 114.8 (20.6) 116.3 (19.7) 0.84
Anaemia (Hb <100 g/L) 17.5% 20.6% 0.65
Hb (anaemic patients at first visit) 85.9 (12.8) 100.8 (18.1) 0.02
Ferritin (μg/L) 131.0 (220.0) 267.5 (359.0) <0.001
Iron deficiency 56.7% (55) 26.8% (26) 0.002
Ferritin (iron deficiency group at first visit) 67.0 (62.0) 185.0 (269.0) <0.001
Results are displayed as mean (SD), median (IQR interval), or percentages.
Figure 2 Comparison of proportions of patients in different medication dosage groups (none, low dose, and high dose) between the first and last visit
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distributions was statistically different. The distribution of
patients according to dosage groups was different between
the first and last visit for MRAs, with higher proportions of
patients being on higher dosages while having no associ-
ated clinically significant deterioration in renal function
and hyperkalaemia.
There are very few studies looking at medication prescrip-
tion in a similar outpatient CKD–HF cohort which we can com-
pare our results with. In a study by Frohlich et al. looking
retrospectively at ACEi/ARB usage in an outpatient HF clinic,
ACEi/ARB dose was successfully increased in 37.3% of eligible
patients7 which is higher than our rate of 33.0%. This differ-
ence could be explained by their exclusion of CKD stage 5
and dialysis patients and the fact that their follow-up period
was fixed at 12 months.7 The varying follow-up period in
our study meant that a proportion of patients was at early
stages of medication optimization. With regard to other pos-
sible factors affecting medication optimization, our
study showed that severity of CKD and nature of HF did
not have an influence on the likelihood of successful initiation
or dose up-titration similar to a study by Heywood et al.2
Risk of hyperkalaemia in patients with successful RAASi
dose up-titration in our study was comparable to that re-
ported in clinical trials. Reported risk of RAASi-related
hyperkalaemia in clinical trials varies depending on study set-
tings, baseline renal function, and severity of HF and can
range from 3% to 7% for ACEi/ARBs8–11 and 2% to 8.0% for
MRAs.12–14 Trials with lower rates of hyperkalaemia have
stricter definition for hyperkalaemia (>6 mmol/L) such as
Candesartan in Heart failure Assessment of mortality and
Morbidity (CHARM) and Randomized Aldactone Evaluation
Study (RALES)10,11,13 or lower proportion of patients with
CKD (33–48%)1 compared to our patient group (100%).
As the analysis looks at only two time points, this study is
unable to capture the complexity of patient management
and medication trials through the length of follow-up. As
the result, worsening renal failure or hyperkalaemia happen-
ing in between these two end points can still be reason be-
hind failure of initiation or dose titration.
There is currently limited research into prognosis of
CKD–HF patients according to HF groups. Two of such stud-
ies have reported different outcomes: a study by Lofman
et al. found similar 1 year mortality rates in all HF groups15
while in Ahmed et al., CKD patients with systolic HF seem
to do worse than those with diastolic HF.16 Patients with
HFrEF in our study suffered the worst outcomes with signif-
icantly higher rates of hospital admissions and death. To
further assess the effectiveness of this novel clinic, it would
be beneficial to conduct a prospective study to compare
outcomes of our patient population to a matched cohort
being followed up in general nephrology and heart failure
clinic.
The fact that patients attending this clinic benefit from
anaemia nurse specialist input and same-day intravenous Iron
administration also means more efficient use of healthcare
resource, minimization of patients’ waiting time, transport
time, and expense.
Conclusions
This is an initial report on a novel inter-disciplinary kidney fail-
ure and heart failure clinic, which had improved prescription of
RAASi agents and MRA dosages in a cohort of patients with
CKD and HF, without resulting clinically significant biochemical
abnormalities. The effectiveness of such clinic can be further
assessed using a prospective study monitoring medication ti-
tration steps, related adverse events, patients’ satisfaction,
as well as outcomes including quality of life, hospitalization,
and mortality rate.
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